Estramustine Compliance and Degarelix-Based Neoadjuvant Therapy in Very High-Risk Prostate Cancer

Study Background and Research Question

Prostate cancer remains the most frequently diagnosed malignancy among men, with high- and very high-risk forms posing substantial therapeutic challenges. Despite advances in surgical technique—such as robot-assisted radical prostatectomy (RARP)—and the integration of androgen deprivation therapy (ADT), biochemical recurrence-free survival (BCRFS) rates for high-risk patients remain suboptimal, with long-term recurrence observed in over 40% of cases. The established limitations of surgery or ADT alone have prompted evaluation of neoadjuvant chemohormonal therapy (NCHT), particularly combinations involving gonadotropin-releasing hormone (GnRH) antagonists and cytotoxic agents. The reference study by Kambe et al. (International Journal of Urology, 2024) addresses a critical, unresolved question: Does compliance with the estramustine phosphate (EMP) component of NCHT, in combination with degarelix acetate as a GnRH receptor antagonist, influence the risk of biochemical recurrence in very high-risk prostate cancer patients post-RARP?

Key Innovation from the Reference Study

This prospective investigation is distinctive for its focus on dose compliance with the cytostatic agent estramustine phosphate within a standardized NCHT regimen featuring degarelix acetate. While prior reports have indicated that NCHT may improve BCRFS in high-risk populations, data regarding the significance of EMP dosing—particularly in the very high-risk subset—have been sparse. The study's innovation lies in its stratification of patients by EMP dose adherence, and in isolating the prognostic value of strict compliance for biochemical recurrence risk in a real-world, prospectively enrolled cohort.

Methods and Experimental Design Insights

Between December 2017 and March 2023, 187 men with NCCN-classified high or very high-risk localized prostate cancer (cTanyN0M0) were prospectively enrolled at a single center. All patients received 6 months of neoadjuvant chemohormonal therapy comprising degarelix acetate (a selective GnRH receptor antagonist) and low-dose EMP, followed by RARP. The cohort was stratified by EMP dose completion: patients who continued with two daily EMP tablets throughout NCHT (completion group) versus those who reduced the dose to one tablet or discontinued (reduction group). Multivariate analyses were performed to assess predictors of biochemical recurrence, defined by PSA criteria. Adverse events (AEs) were meticulously recorded and categorized according to CTCAE standards, enabling robust correlation of toxicity profiles with dose compliance and surgical outcomes. Importantly, patients who discontinued neoadjuvant therapy due to AEs or other reasons prior to 5 months, or entered postoperative castration range, were excluded from the main survival analyses, ensuring a focused evaluation of the intended treatment strategy.

Protocol Parameters

• Neoadjuvant degarelix acetate: Standard clinical regimen for GnRH receptor antagonism; see product information for preclinical and translational dosing details.
• Estramustine phosphate (EMP): Two tablets per day for 6 months, with dose reduction to one tablet as dictated by tolerability.
• Patient selection: High/very high-risk localized prostate cancer (NCCN criteria), cTanyN0M0 staging by imaging and pathology.
• Adverse event monitoring: Weekly assessments per CTCAE v5.0, with dose modifications for grade ≥2 hematologic or thromboembolic toxicity.
• Surgical endpoint: Robot-assisted radical prostatectomy with extended lymph node dissection after completion of NCHT.

Core Findings and Why They Matter

Among 140 patients who completed NCHT and underwent RARP, 82 were classified as very high-risk according to NCCN definitions. The majority (124) maintained the full EMP regimen, while 16 required dose reduction. The most common adverse events included anemia (93%), elevated transaminase levels (36%), and deep vein thrombosis (12.8%), with severe events (acute coronary syndrome, pulmonary embolism) remaining infrequent but clinically significant. Histopathological outcomes were predictably worse in the very high-risk group, reflecting the aggressive disease biology. Crucially, multivariate analysis revealed that both very high-risk status and EMP dose reduction independently predicted increased biochemical recurrence. In very high-risk patients, those with EMP dose reduction had a significantly lower BCRFS compared to those maintaining full dosing. This association did not reach significance in the high-risk (but not very high-risk) subgroup. These results underscore the critical importance of EMP compliance in optimizing outcomes for the most aggressive localized prostate cancers, and suggest that AE management to preserve dosing is a modifiable determinant of long-term recurrence risk (reference study).

Comparison with Existing Internal Articles

Multiple internal resources have explored degarelix acetate's mechanistic and workflow applications in prostate cancer models:

• The article "Degarelix Acetate: Mechanistic Insight and Translational Impact" discusses degarelix's ability to achieve rapid, sustained testosterone suppression, emphasizing its role in both laboratory and clinical hormone modulation strategies. The reference study extends these translational implications by demonstrating degarelix's effectiveness within a chemohormonal backbone in a prospective, real-world clinical setting.
• "Degarelix Acetate: Protocol Optimization in Prostate Cancer Research" provides detailed advice for assay workflow, including dose selection and hormone suppression monitoring. The clinical study by Kambe et al. provides a robust, patient-centered validation of these protocol parameters, particularly regarding the need to maintain hormone suppression and cytostatic dosing for optimal outcomes.
• Insights into adverse event management from the reference paper offer a clinical correlate to preclinical troubleshooting strategies discussed in "Degarelix Acetate: Aggregation Science and Assay Optimization", particularly in terms of reliably achieving hormone secretion inhibition without unacceptable toxicity.

In summary, while existing internal articles focus on workflow, dosing, and mechanistic rationale for degarelix in research and translational contexts, the reference study provides direct clinical evidence that maintaining chemohormonal dose intensity—enabled by effective AE monitoring and management—substantially affects recurrence outcomes in very high-risk patients.

Limitations and Transferability

Several limitations merit mention. The study was conducted at a single institution, potentially limiting generalizability to broader populations and diverse healthcare systems. Furthermore, the analysis was restricted to patients completing at least 5 months of NCHT and not entering postoperative castration range, excluding those with highest toxicity or rapid disease progression. While the study design was prospective, it was not randomized, and EMP dose reduction was dictated by AE profile, potentially introducing bias. Nevertheless, the rigorous prospective data collection, standardized surgical and pathological endpoints, and statistical adjustment for confounders support the validity of the central finding: EMP dose compliance is a key, modifiable driver of biochemical recurrence risk in very high-risk prostate cancer patients managed with degarelix-based NCHT and RARP. For translational researchers, these insights underscore the need for careful protocol design addressing both efficacy and tolerability when modeling or extending such regimens.

Research Support Resources

Researchers aiming to model or extend these workflows in preclinical or translational settings can utilize Degarelix acetate (SKU C8718) for in vitro and in vivo studies requiring robust, selective GnRH receptor antagonism. Degarelix acetate from APExBIO offers high receptor specificity and validated dosing parameters for cell-based and animal models, supporting the design and optimization of hormone suppression strategies paralleling clinical protocols. Integration of adverse event monitoring and dose compliance assessment, as illustrated in the reference study, is recommended for translational fidelity.